Introduction
C holangiocarcinomas (CCAs) comprise heterogeneous hepatobiliary tumors with cholangiocyte differentiation features. CCAs are classified as intrahepatic (iCCA), perihilar, and distal, based on their anatomic location. (1, 2) In the liver, iCCA accounts for 5%-10% of all malignant primary cancers and ranks second after hepatocellular carcinoma (HCC). Importantly, both incidence and mortality rates of iCCA have increased significantly worldwide during the past decades. (2) To date, surgery is the best potentially curative treatment for iCCA but is feasible in less than 40% of cases. For these Abbreviations: CASC15, cancer susceptibility candidate 15; CCA, cholangiocarcinoma; circRNA, circular RNA; EMT, epithelial to mesenchymal transition; GSEA, gene set enrichment analysis; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; IL8, interleukin 8; ISH, in situ hybridization; LCM, laser capture microdissection; lncRNA, long non coding RNA; miRNA, miR, micro RNA; Q-RT-PCR, quantitative reverse-transcription polymerase chain reaction; RNase, ribonuclease; SMAD, SMAD family member; SNAI1, snail family transcriptional repressor 1; TGFb, transforming growth factor beta; TLINC, transforming growth factor beta-induced long noncoding RNA; TLINC-L, long TLINC isoform; TLINC-S, short TLINC isoform.
resectable early stage iCCAs, 5-year survival is about 40%. However, for unresectable advanced iCCA, the median survival is less than 15 months. (2) Although significant progress in understanding the molecular basis of iCCA pathogenesis has been achieved by high throughput strategies, including the identification of genetic, epigenetic, and genomic alterations (e.g., KRAS proto-oncogene guanosine triphosphatase [KRAS] , isocitrate dehydrogenase 1/2 [IDH1/2] mutations, fibroblast growth factor receptor 2 [FGFR2] fusions), there is no approved molecular targeted therapy that significantly improves patient survival in iCCA. (1, 3) Thus, iCCA remains characterized by limited therapeutic options and very poor prognosis. (1, 3) One histologic feature of iCCA is the presence of a prominent desmoplastic stroma that is known to contribute to tumor onset and progression. (4, 5) While previous studies largely focused on identifying molecular alterations in tumor cells, we recently characterized genomic alterations that occur in the tumor microenvironment of iCCA. (6) Thus, by combining laser microdissection and gene expression profiling, we demonstrated that the expression of transforming growth factor beta (TGFb) in the stroma of iCCA predicts a poor prognosis, suggesting that TGFb may represent a potential therapeutic target in iCCA. (6) TGFb is a pleiotropic cytokine that controls fundamental cellular processes associated with carcinogenesis (e.g., proliferation, apoptosis, invasion, angiogenesis, immunity). (7) However, the actions of TGFb in cancer are complex because TGFb exhibits either tumorsuppressive or tumor-promoting properties, depending on the tumor stage. At an early stage, TGFb exerts potent antiproliferative properties on precancerous epithelial cells, notably by inducing genes with cytostatic actions (e.g., cyclin-dependent kinase inhibitor 1A [CDKN1A]). At an advanced stage, cells become resistant to the cytostatic effects of TGFb, which then promotes tumor growth and metastatic progression, particularly as a potent inducer of epithelial-mesenchymal transition (EMT). (7, 8) To date, the molecular mechanisms switching the TGFb actions from tumor suppression toward tumor promotion are not fully understood and may depend on the cellular context. (9, 10) Gene mutations in the canonical TGFb signaling (e.g., SMAD family member 4 [SMAD4]) and crosstalk with proliferative pathways have been proposed to contribute to the loss of the tumor suppressor arm of TGFb in several cancers. (9) In addition, recent evidence demonstrated that long noncoding RNA (lncRNA) could mediate the prometastatic properties of TGFb. (11, 12) LncRNAs form a large and diverse class of long RNA molecules (>200 nucleotides) that do not encode proteins. LncRNAs emerged as key regulators involved in human carcinogenesis, including liver cancers. (13, 14) Here, we characterized the transcriptional response of iCCA cell lines to TGFb and identified novel TGFb-regulated genes, including a lncRNA that we named TGFb-induced lncRNA (TLINC, formerly known as LINC00340 and cancer susceptibility candidate 15 [CASC15]). TLINC is induced by TGFb in several settings, and the expression of specific isoforms correlates with an EMT phenotype. TLINC is strongly up-regulated in human iCCA and is associated with an enhanced expression of proinflammatory cytokines, including interleukin 8 (IL8). Finally, circular isoforms of TLINC are highlighted as promising biomarkers in patients with iCCA.
Materials and Methods

CELL CULTURE AND REAGENTS
HuCCT1 (RCB-1960) and Huh28 (RCB-1943) CCA cell lines were purchased at the RIKEN BioResource Center (Tsukuba-shi, Japan). Cells were grown in Roswell Park Memorial Institute 1640 medium (HuCCT1) or minimal essential medium (Huh28) supplemented with 100 U/mL penicillin, 100 lg/mL streptomycin, and 10% fetal bovine serum. HCC cell lines were purchased from ATCC and cultured as described. (15) LX2 cells were grown as described. (16) Freshly isolated human hepatocytes were purchased from Biopredic International (St. Gr egoire, France). Cells were cultured at 37 8C in a 5% CO 2 atmosphere, and overnight serum starvation was performed before each treatment. Unless otherwise specified, cells were treated with 1 ng/mL recombinant human TGFb (R&D Systems, Minneapolis, MN) and 10 mM TGFb inhibitors (Sigma-Aldrich, St. Louis, MO).
TGFb SENSOR CELL LINES AND LUCIFERASE ACTIVITY
Stable TGFb sensor cell lines were generated by using a pCignal Lenti-SMAD Reporter assay (Qiagen, Courtabeuf, France) according to the manufacturer's instructions. Briefly, cells were transduced with lentiviral particles (multiplicity of infection, 10; 8 mg/mL SureENTRY transduction reagent) and selected with 1 mg/mL puromycin for 5 days. Luciferase activity was determined with the Firefly Luciferase Assay System (Promega, Madison, WI) and normalized by the number of viable cells evaluated by a PrestoBlue cell viability reagent (Invitrogen, Carlsbad, CA).
DNA TRANSFECTION
DNA constructs were kindly provided by Dr. Kristina A. Cole (Children's Hospital of Philadelphia, Philadelphia, PA) and Dr. Sumio Sugano (University of Tokyo, Tokyo, Japan). All constructs were amplified by transformation of One Shot TOP10 Escherichia coli (Invitrogen) and validated by DNA sequencing (Supporting Table S1 ) after DNA purification (Nucleobond Xtra plasmid maxiprep kit; Macherey Nagel, Hoerdt, France). DNA transfection was performed by using Lipofectamine 2000 (Invitrogen).
PROTEIN ANALYSIS
A Quantikine enzyme-linked immunosorbent assay human TGFb1 immunoassay (R&D Systems) was used to evaluate the expression of TGFb in the supernatant of cell cultures collected 24 hours after serum starvation. Protein analysis by immunoblotting was performed as described. (17) Human anti-E-cadherin (CDH1) (AF648; R&D Systems) and anti-vimentin (VIM) (B01P; Abnova) antibodies were used.
GENE EXPRESSION PROFILING
Total RNA, including lncRNA and micro RNA (miRNA, miR), was purified with an miRNAeasy kit (Qiagen). Genome-wide expression profiling was performed using the low-input QuickAmp labeling kit and human SurePrint G3 8x60K probes pangenomic microarrays (Agilent Technologies, Santa Clara, CA) as described. (15) These microarrays include 26,083 Entrez genes and 30,606 lncRNAs. Gene expression data were processed using Feature Extraction and GeneSpring software (Agilent Technologies). Microarray data sets have been deposited into the public Gene Expression Omnibus database under accession numbers GSE102109 and GSE102110. Gene set enrichment analysis (GSEA) was performed using the Java tool developed at the Broad Institute (Cambridge, MA). The Enrichr algorithm (http://amp.pharm. mssm.edu/Enrichr) was also used to identify key genes associated with relevant signaling pathways.
QUANTITATIVE REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION
Quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR) was performed as described (16) by using a SYBR Green master mix (Applied Biosystems, Carlsbad, CA). A mixture of deoxythymidine oligomer (250 ng) and random hexamers (100 ng) was used to prime the RT reaction of 1 mg total RNA (Superscript III RT; Invitrogen). A list of DNA primers used in this study is provided in Supporting Table S2 .
FUNCTIONAL TESTS
Cell viability was evaluated using a PrestoBlue reagent (Invitrogen). Data were expressed as relative cell viability compared to untreated cells transfected with the control plasmid set as 1. Cell migration and invasion were evaluated using BD BioCoat Matrigel Invasion Chambers (BD Biosciences) as described. (16) Briefly, 4 3 10 4 cells were plated in serum-free medium either on an 8-mm pore-size positron emission tomography membrane insert coated with a layer of matrigel basement membrane matrix (invasion test) or on an 8-mm pore-size positron emission tomography control membrane insert (migration test). The lower compartment contained medium with 10% fetal bovine serum as a chemoattractant. After incubation for 48 hours, we removed the cells remaining on the upper surface of the membrane with a cotton swab, fixed cells in 4% paraformaldehyde that had passed through to the lower surface of the membrane, and stained the fixed cells with 1% crystal violet. We scored invasive and migrating cells per membrane under a analysis was performed by t test (*P < 0.05; **P < 0.01; ***P < 0.001); n 3 replicates. Data represent mean 6 SD. Abbreviations: mRNA, messenger RNA; MW, molecular weight. light microscope at a 5 3 magnification (n 5 3 independent experiments). The number of migrating and invasive cells after transfection of TLINC was normalized relative to the number of migrating and invasive cells after transfection of the control plasmid, which was set to 1.
HUMAN iCCA SAMPLES AND TISSUE MICROARRAY
Freshly frozen and formalin-fixed paraffin-embedded human iCCA samples were obtained through the national liver biobanks network. Written informed consent was obtained from all patients. The study protocol fulfilled national laws and regulations and was approved by the local ethics committee and the institutional review board of the Institut National de la Sant e et de la Recherche M edicale (IRB00003888). Tissue microarrays were performed using a Minicore 3 Tissue Arrayer (Excilone, Vicq, France) as described. (6) 
LASER CAPTURE MICRODISSECTION
Laser capture microdissection (LCM) was performed using an Arcturus Veritas Microdissection system (Applied Biosystems) as described. (6) Briefly, serial sections of 10-mm frozen tissues were mounted onto PEN membrane glass slides prior to LCM of biliary epithelial cells and fibrous tissue from tumor and nontumor parts. Total RNA was purified using an Arcturus Picopure RNA isolation kit (Applied Biosystems). or presence (black bars) of 1 ng/mL TGFb. Statistical analysis was performed by t test (*P < 0.05; **P < 0.01; ***P < 0.001); n 3 replicates. Data represent mean 6 SD. Abbreviation: Ctrl, control. 
IN SITU HYBRIDIZATION
Specific in situ hybridization (ISH) riboprobes were designed to evaluate the expression of TLINC-S and TLINC-T transcripts (Supporting Table S1 ). Sense and antisense riboprobes were generated by in vitro transcription from PCR products incorporating the promoter of T7 RNA polymerase. In vitro transcription was performed with 40 units T7 RNA Polymerase (Agilent) in the presence of 0.35 mM digoxygenin-11-UTP (Roche Diagnostics, Meylan, France). ISH was performed on the Discovery Automated IHC Stainer using the Ventana Detection Kit (Ventana Medical Systems, Tucson, AZ). Staining was performed using an anti-digoxygenin-horseradish peroxidase antibody (Roche Diagnostics), and signal detection was performed using a nitro-blue tetrazolium/5-bromo-4-chloro-3 0 -indolyphosphate or a Discovery purple kit (Ventana Medical Systems).
CIRCULAR RNA ANALYSIS
RT-PCR using convergent and divergent primers combined with ribonuclease (RNase) R (Epicentre, Middleton, WI) treatment (1 m/mg, 37 8C, 1 hour) was used to detect linear and circular transcripts of TLINC and actin beta (ACTB). The sequence of DNA primers is provided in Supporting Table S2 .
Results
ENDOGENOUS TGFb ACTIVATION IN Huh28 CELLS
HuCCT1 and Huh28 cells were used to study the impact of TGFb on iCCA cells. The two cell lines have different phenotypic features that reflect tumor heterogeneity. HuCCT1 cells exhibit an epithelioidlike phenotype associated with a cobblestone-like morphology and numerous cell-to-cell junctions compared to Huh28 cells, which exhibit a mesenchymal-like phenotype associated with a spindle and polygonal morphology together with prominent cytoskeleton fibers (Fig. 1A) . Epithelioid and mesenchymal-like phenotypes were further characterized by the expression of CDH1 and VIM markers in HuCCT1 cells and Huh28 cells, respectively, both at the RNA and protein level (Fig. 1A) . Marked differences in pangenomic expression profiles were also highlighted between HuCCT1 and Huh28 cells and validated by Q-RT-PCR ( Fig. 1B; Supporting Fig. S1A ).
Interestingly, GSEA, using the Kyoto Encyclopedia of Genes and Genomes signaling pathways, demonstrated that a TGFb signature was significantly enriched (P < 0.001) at the basal level in mesenchymal Huh28 cells (Fig. 1B) . Endogenous activation of the TGFb pathway in Huh28 cells was further validated by a significantly enhanced secretion of TGFb (Fig.  1C) that correlated with enhanced luciferase activity as detected in engineered SMAD sensor cell lines (Fig.  1D) . A higher expression of TGFb target genes (e.g., snail family transcriptional repressor 1 [SNAI1], collagen type IV alpha 1 chain [COL4A1], SMAD7) in Huh28 cells was also validated by Q-RT-PCR ( Fig.  1E; Supporting Fig. S1A ) as well as a reduced expression of SMAD7, a well-known TGFb transcriptional target, when cells were cultured in the presence of TGFb inhibitors (Fig. 1F) . Altogether, these data demonstrate that Huh28 cells exhibit a mesenchymal phenotype associated with basal and endogenous activation of the TGFb pathway.
NEW TGFb TARGET GENES IN iCCA CELLS
HuCCT1 and Huh28 cells were treated with 1 ng/ mL TGFb for 16 hours. Gene expression profiling using pangenomic microarrays identified 859 probes in HuCCT1 cells ( Fig. 2A) and 491 probes in Huh28 cells (Fig. 2B ) that were significantly deregulated by TGFb (P < 0.001; fold change >2). A Venn diagram analysis, including genes differentially expressed between HuCCT1 and Huh28 cells at a basal level (Fig. 1B) , identified a set of 48 probes (42 nonredundant annotated genes) that were recurrently deregulated by TGFb in all three experimental settings ( Fig.  2C ; Table 1 ). The deregulation of well-known positive (e.g., serpin family E member 1 [SERPINE1], connective tissue growth factor [CTGF]) and negative (e.g., baculoviral inhibitor of apoptosis protein repeat containing 3 [BIRC3]) TGFb target genes was confirmed by Q-RT-PCR on independent RNA samples ( Fig.  2D; Supporting Fig. S1B ). GSEA was also performed in all specific gene subsets and demonstrated that the 42 common genes were significantly associated with TGFb and SMAD2/3 and related to EMT (Supporting Fig. S2 ). Importantly, this common signature comprised genes not known to be regulated by TGFb, including several lncRNAs (e.g., LINC00312, LINC00340). Notably, two microarray probes for LINC00340 were induced by TGFb (Table 1) .
LINC00340/CASC15/TLINC IS A NOVEL TGFb-INDUCED lncRNA
LINC00340 is known as cancer susceptibility candidate 15 (CASC15) located on chromosome 6p22. CASC15 was reported to act as a tumor suppressor in neuroblastoma (18) and to promote tumor progression and phenotype switching in melanoma. (19) To further characterize LINC00340 biological activities in iCCA, we first validated the microarray expression data by Q-RT-PCR. LINC00340 was induced by TGFb in both HuCCT1 and Huh28 cells, and a significant higher expression in Huh28 cells at the basal level was confirmed (Fig. 3A) . Repression of LINC00340 and SMAD7 was observed in Huh28 cells treated with inhibitors of the TGFb pathway (Fig. 3B) . Time-course experiments also demonstrated increased expression of LINC00340 by TGFb, both in HuCCT1 and Huh28 cells (Fig. 3C) . Interestingly, LINC00340 was induced by TGFb in nontransformed human primary hepatocytes, and the induction was abolished in the presence of a TGFb inhibitor and Panc-1 (pancreatic cancer) cells (right two panels) (1 ng/mL TGFb for 16 hours). Statistical analysis was performed by t test (*P < 0.05; **P < 0.01; ***P < 0.001); n 3 replicates. Data represent mean 6 SD. Abbreviations: DMSO, dimethyl sulfoxide; inh., inhibitor; mRNA, messenger RNA; ns, not significant. (Fig. 3D ). In addition, LINC00340 was induced by TGFb in several human HCC cell lines as well as in LX2-activated hepatic stellate cells (Fig. 3E) . Finally, induction by TGFb occurred also in nonhepatic cell lines, such as pancreatic Panc-1 (Fig. 3E) . Altogether, these data demonstrate that LINC00340 is a novel and general transcriptional target of TGFb. We therefore named it TGFb-induced lncRNA or TLINC.
INDUCTION OF TWO TLINC ISOFORMS LINKED TO AN EMT PHENOTYPE
Previous studies demonstrated that TLINC is located on a complex locus that produces multiple transcripts by alternative splicing, including a short (TLINC-S) and a long (TLINC-L) isoform, as shown in Fig. 4A . (18, 19) These two isoforms have been functionally associated with either tumor suppressive (TLINC-S) (18) or tumor promoting (TLINC-L) (19) functions in neuroblastoma and melanoma, respectively. Because our previous gene expression analysis by microarray (Fig. 2) and Q-RT-PCR (Fig. 3) could not distinguish the two isoforms (primer set L 1 S), we next evaluated TLINC-S and TLINC-L with specific sets of primers (Fig. 4A) . TLINC-L was induced by TGFb in HuCCT1 cells and TLINC-S in Huh28 cells, as demonstrated by Q-RT-PCR (Fig. 4B) . ISH demonstrated that the two isoforms were expressed in both the cytoplasm and the nucleus (Fig. 4C) .
FUNCTIONAL CHARACTERIZATION OF TLINC ISOFORMS
Gain of function experiments were performed using DNA constructs designed to specifically overexpress TLINC-L and TLINC-S (Supporting Fig. S3A-C) . No significant effect was observed on cell viability (Supporting Fig. S3D ) and cell invasion (Fig. 5A) ; however, overexpression of TLINC-L increased cell migration (Fig. 5A) . In order to get insights into the molecular mechanisms involved, gene expression profiling was performed on HuCCT1 cells after TLINC-L overexpression. Numerous genes were repressed (Fig. 5B) , whereas several inflammation-associated genes, including cytokines and chemokines (e.g., IL6, IL8, C-X-C motif chemokine ligand 1 [CXCL1]) were induced together with LINC00340/TLINC (Fig. 5B) . Accordingly, an immune response gene signature was significantly enriched in the gene expression profiles of HuCCT1 cells overexpressing TLINC-L ( Fig. 5C ; Supporting Table S3 ). The enrichment of a described (20) cell migration signature supported the phenotype observed after TLINC-L overexpression (Fig. 5C ). Although no obvious change was observed on cell morphology after TLINC-L transfection, EMT-associated SNAI2 was enriched in the gene expression profiles of TLINC-L transfected cells (Supporting Table S4 ). A significant enrichment of TGFb target genes was also observed, suggesting that TLINC-L may act as a feedback regulator of the TGFb pathway (Fig. 5C ). However, experimental data using SMAD sensor cell lines refuted this hypothesis (Supporting Fig. S3E ). In agreement In situ hybridization using TLINC-L and TLINC-S riboprobes highlights a nuclear and cytoplasmic location of both TLINC isoforms (HuCCT1 cells treated with 1 ng/mL TGFb). Scale, 100 mm. Statistical analysis was performed by t test (*P < 0.05; **P < 0.01; ***P < 0.001); n 3 replicates. Data represent mean 6 SD. Abbreviations: (AS), antisense; mRNA, messenger RNA; ns, not significant.
with the identified immune signature, increased expression of IL8 was confirmed after TLINC overexpression (Fig. 5D) . As a potent inducer of cell motility, IL8 may contribute to the observed phenotype by creating a gradient for the migration of cancer cells.
INCREASED EXPRESSION OF TLINC IN HUMAN iCCA
We next evaluated the clinical relevance of TLINC expression in human resected iCCA. TLINC was shown to be induced both in tumor biliary epithelial cells and in the stroma compared to their nontumor counterparts (Fig. 6A) . Overexpression of TLINC in iCCA tumors was validated by ISH on tissue microarrays (Fig. 6A) . Interestingly, Q-RT-PCR on 22 resected human iCCA demonstrated that the expression of TLINC-L and TLINC-S was tightly correlated (Fig. 6B) . A detailed analysis by ISH on human resected iCCA confirmed that both TLINC isoforms were expressed in tumor cholangiocytes and in cells from the tumor microenvironment. In the nontumor liver, TLINC was only expressed in remodeled portal areas with signs of ductular reaction and inflammation ( Fig. 6C; Supporting Fig. S4 ). analysis was performed by t test (*P < 0.05; **P < 0.01; ***P < 0.001); n 3 replicates. Data represent mean 6 SD. Abbreviations: C, control; CCL2, chemokine (C-C motif) ligand 2; CTRL, control; CXCR1, chemokine (C-X-C motif) receptor 1; HNF, hepatocyte nuclear factor; L, long; mRNA, messenger RNA; NES, normalized enrichment score; p, plasmid [for pControl and pTLINC-L]; RABL2A, RAB, member of RAS oncogene family like 2A; S, short; TP53AIP1, tumor protein p53 regulated apoptosis inducing protein 1; TNF, tumor necrosis factor. (C) ISH analysis of TLINC-L and TLINC-S expression using specific antisense and sense riboprobes. In the tumor part, TLINC was expressed in both epithelial cells (white arrow) and in the stroma (black arrow). In the nontumor part, TLINC was only expressed in remodeled portal areas with signs of ductular reaction. Scale bars: 5 mm (left panels) and 100 mm (right panels). (D) Expression of TLINC identifies human iCCA with specific gene expression profiles. Median expression of TLINC was used to define high and low expression groups (n 5 22 patients). (E) Example of signatures significantly enriched in the gene expression profiles of iCCA with high versus low TLINC expression, as evaluated by GSEA. (F) Correlation between the expression of TLINC and CXCL8 in 22 human iCCAs. Abbreviations: (AS), antisense; BEC, biliary epithelial cells; EEF1A1, eukaryotic translation elongation factor 1 alpha 1; EIF4B, eukaryotic translation initiation factor 4B; ELK1, ELK1, ETS transcription factor; ITGB3, integrin subunit beta 3; HCP, high-CpG-density promoters; MAP3K4, mitogen-activated protein kinase kinase kinase 4; MEF, mouse embryonic fibroblast; NF-kB subunit; NES, normalized enrichment score; NT, nontumor; PDGFRB, platelet derived growth factor receptor beta; RELA, RELA proto-oncogene; RPL6, ribosomal protein L6; RPL21, ribosomal protein L21; RPS2, ribosomal protein S2; RUNX1, runt related transcription factor 1; (S), sense; SF3B6, splicing factor 3b subunit 6; SKIL, SKI like proto-oncogene; SRSF7, serine and arginine rich splicing factor 7; T, tumor.
TLINC EXPRESSION DEFINES SPECIFIC SUBSETS OF HUMAN iCCA
Gene expression profiling was performed on 22 resected human iCCA, and a specific signature was defined on the basis of TLINC expression (Fig. 6D) . High expression of TLINC correlated with a high expression of TGFb target genes and inflammationassociated genes, as previously observed in cell lines ( Fig. 6D; Supporting Fig. S5 ). In addition, GSEA demonstrated that up-regulated genes in high-TLINC-expressing tumors were significantly associated with the H3K27Me3 repressive epigenetic mark signature, while down-regulated genes were linked to protein metabolism and included numerous genes encoding ribosomal components ( Fig. 6D,E ; Supporting Fig. S6 ). Among the chemokines induced in HuCCT1 cells directly overexpressing TLINC (Fig.  5B) and possibly contributing to a migration phenotype, IL8 was found to be significantly correlated with TLINC expression in human iCCA tumors (Fig. 6F ).
EXPERIMENTAL EVIDENCE OF TLINC CIRCULAR ISOFORMS
A genome-wide bioinformatic analysis of RNAsequencing data previously reported a 204-nucleotide circular isoform of LINC00340/TLINC, probably derived from exon E7. This isoform was one of the most highly expressed circular RNAs (circRNAs) in H1-human embryonic stem cells. (21) To evaluate the putative expression of such circular isoforms in iCCA, we designed specific sets of convergent and divergent primers from exons E7 and E8 of TLINC (Fig. 7A) . ACTB was used as a housekeeping gene control that was highly expressed and without prior evidence of a circular isoform. Interestingly, by combining RNase R treatment and RT-PCR experiments, we provide evidence of the existence of several RNase R-resistant circular TLINC isoforms not only in iCCA cells treated with TGFb (Fig. 7B ) but also in resected human iCCA tumors (Fig. 7C) .
Discussion
The molecular mechanisms involved in iCCA carcinogenesis are complex and involve multiple interactions between tumor cells and their microenvironment.
(1) We previously demonstrated that active TGFb signaling is an important feature in the iCCA microenvironment (6) ; however, a deep characterization of the impact of TGFb on tumor cells at the transcriptome level was lacking in iCCA. In this study, we first validated suitable experimental cellular models to study TGFb signaling in iCCA cells. Particularly, we provided strong experimental evidence that Huh28 cells For ACTB (a housekeeping gene highly expressed), no amplification was observed after RNase R treatment. By using a specific set of divergent primers located on exons E7 and E8, several TLINC circular isoforms were highlighted (black arrowheads). (C) RNAs were extracted from 16 human iCCA tumors. RT-PCR analysis was performed using a specific set of divergent primers located on exons E7 and E8, as indicated at the top of the panels (a, E7R/ E8F; b, E7R/E7F). Black arrowheads highlight TLINC circular isoforms. Abbreviations: bp, base pair; MW, molecular weight.
exhibit an endogenous activation of TGFb, which correlates with a mesenchymal phenotype. This cell line may thus be relevant to test TGFb inhibitors for therapeutic purposes, as was suggested in liver cancers. (22) In addition, we provided the first TGFb transcriptomic signature in iCCA cells, which allowed us to identify novel TGFb transcriptional targets, including coding and noncoding genes, both in vitro and in resected human iCCA.
Few studies have reported a deregulation of lncRNA in iCCA. (23, 24) As an example, oncogenic metastasisassociated lung adenocarcinoma transcript 1 (MALAT1) lncRNA was shown to promote proliferation and invasion of CCA cell lines by activating the phosphoinositide 3-kinase/protein kinase B signaling pathway. (24) Here, we provide the first report of lncRNA directly regulated by TGFb in iCCA, supporting the previous description of TGFb-regulated lncRNA in other cancer types. (11, 12) Notably, lncRNA activated by TGF-b was shown to induce EMT and to promote HCC cell invasion through a TGFb/miR-200/zinc finger E-box binding axis. (12) Similarly, TGFb-induced lncRNA-HIT was shown to promote EMT in breast cancer, notably by decreasing the expression of CDH1. (11) By comparing the transcriptome profiles of HuCCT1 and Huh28 cells at the basal level and after TGFb treatment, we identified a robust signature made of 42 nonredundant genes. This signature was validated by including well-known TGFb target genes (e.g., SERPINE1, IL11, CTGF, BCL2 modifying factor [BMF], SNAI1) reported in multiple cell types, including hepatocytes. (25) Importantly, this approach highlighted several novel TGFbinduced lncRNA, including LINC00312, LINC00313, and LINC00340 (TLINC), possibly involved in TGFb signaling. LINC00312 has been reported to inhibit the migration and invasion of bladder cancer cells by targeting miR-197-3p. (26) High expression of LINC00313 has been associated with a poor prognosis and metastasis in lung cancer. (27) Experimental data on TLINC were more complex given that several isoforms were reported to exhibit either tumor-suppressive or tumor-promoting features in various types of cancer. (18, 19) Thus, in neuroblastoma, a short isoform was associated with tumor suppression by hampering cell growth and migration, and a lower expression of this short isoform was found in advanced tumors associated with a poor survival. (18) Conversely, a long isoform of TLINC was reported in metastatic melanoma and associated with tumor progression. (19) The differences in the basal expression and induction by TGFb of TLINC isoforms in HuCCT1 and Huh28 cell lines suggest that the function of TLINC is highly dependent on the cellular context, as known for several TGFb target genes. (10) Although TLINC deregulation has been reported in cancer, (18, 19) we provide the first evidence that TLINC is a common transcriptional target of TGFb not only in liver cancer (iCCA and HCC) but also in other cancer types, including pancreatic cancer. Interestingly, we demonstrated that TLINC is also up-regulated by TGFb in cells from the tumor microenvironment, as evidenced by the analysis of its expression in activated hepatic stellate cells (LX2) and in human iCCA tumors by ISH and LCM of the stroma. These data suggest that TLINC may play a role in TGFbinduced remodeling of the tumor microenvironment. Supporting this hypothesis, our experimental data show that ectopic expression of TLINC directly impacts the expression of several inflammatory mediators, including chemokine IL8. Increased expression of IL8 has been reported in cancer and is associated with important changes within the tumor microenvironment, including promotion of angiogenesis, infiltration of neutrophils and tumor-associated macrophages, and migration of cancer cells. (28, 29) Interestingly, a functional link has been established between the expression of IL8 and nuclear paraspeckle assembly transcript 1 [NEAT1], another lncRNA that we found to be induced in cells transfected with the TLINC DNA construct (Fig. 5B) . Indeed, it was demonstrated that NEAT1-dependent relocation of a splicing factor proline/glutamine-rich from the promoter region of the IL8 gene to paraspeckle led to the transcriptional activation of IL8. (30) One can hypothesize that TLINC acts as a structural component of paraspeckles and that interaction with NEAT1 may result in IL8 expression. This hypothesis is in agreement with the partial nuclear location of TLINC. The enrichment of a gene signature associated with repressive marks H3K27me3 in iCCA tumors characterized by a high expression of TLINC may also suggest a role of TLINC in epigenetic silencing, as was described for other lncRNAs, such as Kcnq1ot1 antisense. (31) Similarly, enrichment of a gene signature associated with protein metabolism in iCCA with low TLINC expression together with the cytoplasmic expression of TLINC may suggest a role of TLINC in translation, as described for lncRNA growth arrest specific 5 (GAS5), which interacts with the translational machinery to inhibit c-Myc translation. (32) Another interesting aspect is the restricted expression of TLINC in remodeled portal areas with signs of ductular reaction in nontumor livers. These areas are usually associated with activation of the cancer stem cell compartment. (33) Supporting a putative role of TLINC in cancer stem cell biology, TLINC has been reported to be highly expressed in human embryonic stem cells. (21, 34) At the functional level, we showed that TLINC-L overexpression in HuCCT1 cells resulted in increased cell migration. Although the underlying molecular mechanisms are still to be clarified, SNAI2 was found to be enriched in the gene expression profiles of TLINC-L transfected cells, suggesting that the type of migration could be partly related to EMT. Other genes found to be tightly correlated with TLINC expression in human iCCA tumors may also contribute to the observed phenotypes. As an example, platelet-derived growth factor receptor beta (PDGFRB) has been associated with the aggressive behavior of several types of tumors. (35) Notably, PDGFRB has been shown to promote liver metastasis formation of mesenchymal-like colorectal tumor cells. (36) Finally, we provide experimental evidence of circular isoforms of TLINC that may represent putative, relevant, noninvasive biomarkers for iCCA. Indeed, recent data demonstrated that circRNAs are enriched in extracellular vesicles, including exosomes, compared to their linear counterparts. (37, 38) The circular structure of circRNAs renders them more stable and resistant to degradation by exonucleases. Thus, pangenomic profiling of circRNA abundance is emerging in cancer, and several expression signatures have been reported, notably in HCC. (39) Our study provides the first report of circRNA expression in iCCA. The function of circRNA-TLINC remains to be explored, but several experimental data demonstrated that circRNAs may act as sponges for miRNA and RNA binding proteins. With respect to the TGFb pathway, circRNA_010567 has been recently shown to promote TGFb-induced myocardial fibrosis by directly suppressing miR-141, which naturally targets TGFb. (40) In conclusion, our study identifies novel TGFb transcriptional target genes in iCCA, including an lncRNA that may represent a promising biomarker for iCCA.
